Whether the new CAR-T therapy ‘Kymriah’ will be applied insurance benefit is receiving wide attention.

According to industry sources, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy ‘Kymriah' will be deliberated as an agenda by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee on the 13th of this month, 3 months after the agenda passed the Cancer Disease Deliberation Committee in October last year.

Specifically, the drug is indicated for ▲ adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy, and ▲ patients up to 25 years of age with B-cell precurso